The clinical significance of occult gastrointestinal primary tumours in metastatic cancer: A population retrospective cohort study

Malek B. Hannouf, Eric Winquist, Salaheddin M. Mahmud, Muriel Brackstone, Sisira Sarma, George Rodrigues, Peter K. Rogan, Jeffrey S Hoch, Gregory S. Zaric

Research output: Contribution to journalArticle

Abstract

Purpose The purpose of this study was to estimate the incidence of occult gastrointestinal (GI) primary tumours in patients with metastatic cancer of uncertain primary origin and evaluate their influence on treatments and overall survival (OS). Materials and Methods We used population heath data from Manitoba, Canada to identify all patients initially diagnosed with metastatic cancer between 2002 and 2011. We defined patients to have "occult" primary tumour if the primary was found at least 6 months after initial diagnosis. Otherwise, we considered primary tumours as "obvious." We used propensity-score methods to match each patient with occult GI tumour to four patients with obvious GI tumour on all known clinicopathologic features. We compared treatments and 2-year survival data between the two patient groups and assessed treatment effect on OS using Cox regression adjustment. Results Eighty-three patients had occult GI primary tumours, accounting for 17.6% of men and 14% of women with metastatic cancer of uncertain primary. A 1:4 matching created a matched group of 332 patients with obvious GI primary tumour. Occult cases compared to the matched group were less likely to receive surgical interventions and targeted biological therapy, and more likely to receive cytotoxic empiric chemotherapeutic agents. Having an occult GI tumour was associated with reduced OS and appeared to be a nonsignificant independent predictor of OS when adjusting for treatment differences. Conclusion GI tumours are the most common occult primary tumours in men and the second most common in women. Patients with occult GI primary tumours are potentially being undertreated with available GI site-specific and targeted therapies.

Original languageEnglish (US)
Pages (from-to)183-194
Number of pages12
JournalCancer Research and Treatment
Volume50
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Cohort Studies
Retrospective Studies
Population
Neoplasms
Survival
Research Design
Manitoba
Therapeutics
Propensity Score
Biological Therapy
Canada

Keywords

  • Cohort studies
  • Gastrointestinal neoplasms
  • Information storage and retrieval
  • Neoplasm metastasis
  • Propensity score
  • Research design
  • Unknown primary neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hannouf, M. B., Winquist, E., Mahmud, S. M., Brackstone, M., Sarma, S., Rodrigues, G., ... Zaric, G. S. (2018). The clinical significance of occult gastrointestinal primary tumours in metastatic cancer: A population retrospective cohort study. Cancer Research and Treatment, 50(1), 183-194. https://doi.org/10.4143/crt.2016.532

The clinical significance of occult gastrointestinal primary tumours in metastatic cancer : A population retrospective cohort study. / Hannouf, Malek B.; Winquist, Eric; Mahmud, Salaheddin M.; Brackstone, Muriel; Sarma, Sisira; Rodrigues, George; Rogan, Peter K.; Hoch, Jeffrey S; Zaric, Gregory S.

In: Cancer Research and Treatment, Vol. 50, No. 1, 01.01.2018, p. 183-194.

Research output: Contribution to journalArticle

Hannouf, MB, Winquist, E, Mahmud, SM, Brackstone, M, Sarma, S, Rodrigues, G, Rogan, PK, Hoch, JS & Zaric, GS 2018, 'The clinical significance of occult gastrointestinal primary tumours in metastatic cancer: A population retrospective cohort study', Cancer Research and Treatment, vol. 50, no. 1, pp. 183-194. https://doi.org/10.4143/crt.2016.532
Hannouf, Malek B. ; Winquist, Eric ; Mahmud, Salaheddin M. ; Brackstone, Muriel ; Sarma, Sisira ; Rodrigues, George ; Rogan, Peter K. ; Hoch, Jeffrey S ; Zaric, Gregory S. / The clinical significance of occult gastrointestinal primary tumours in metastatic cancer : A population retrospective cohort study. In: Cancer Research and Treatment. 2018 ; Vol. 50, No. 1. pp. 183-194.
@article{4201b58824454bf694aab56008eb09aa,
title = "The clinical significance of occult gastrointestinal primary tumours in metastatic cancer: A population retrospective cohort study",
abstract = "Purpose The purpose of this study was to estimate the incidence of occult gastrointestinal (GI) primary tumours in patients with metastatic cancer of uncertain primary origin and evaluate their influence on treatments and overall survival (OS). Materials and Methods We used population heath data from Manitoba, Canada to identify all patients initially diagnosed with metastatic cancer between 2002 and 2011. We defined patients to have {"}occult{"} primary tumour if the primary was found at least 6 months after initial diagnosis. Otherwise, we considered primary tumours as {"}obvious.{"} We used propensity-score methods to match each patient with occult GI tumour to four patients with obvious GI tumour on all known clinicopathologic features. We compared treatments and 2-year survival data between the two patient groups and assessed treatment effect on OS using Cox regression adjustment. Results Eighty-three patients had occult GI primary tumours, accounting for 17.6{\%} of men and 14{\%} of women with metastatic cancer of uncertain primary. A 1:4 matching created a matched group of 332 patients with obvious GI primary tumour. Occult cases compared to the matched group were less likely to receive surgical interventions and targeted biological therapy, and more likely to receive cytotoxic empiric chemotherapeutic agents. Having an occult GI tumour was associated with reduced OS and appeared to be a nonsignificant independent predictor of OS when adjusting for treatment differences. Conclusion GI tumours are the most common occult primary tumours in men and the second most common in women. Patients with occult GI primary tumours are potentially being undertreated with available GI site-specific and targeted therapies.",
keywords = "Cohort studies, Gastrointestinal neoplasms, Information storage and retrieval, Neoplasm metastasis, Propensity score, Research design, Unknown primary neoplasms",
author = "Hannouf, {Malek B.} and Eric Winquist and Mahmud, {Salaheddin M.} and Muriel Brackstone and Sisira Sarma and George Rodrigues and Rogan, {Peter K.} and Hoch, {Jeffrey S} and Zaric, {Gregory S.}",
year = "2018",
month = "1",
day = "1",
doi = "10.4143/crt.2016.532",
language = "English (US)",
volume = "50",
pages = "183--194",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "1",

}

TY - JOUR

T1 - The clinical significance of occult gastrointestinal primary tumours in metastatic cancer

T2 - A population retrospective cohort study

AU - Hannouf, Malek B.

AU - Winquist, Eric

AU - Mahmud, Salaheddin M.

AU - Brackstone, Muriel

AU - Sarma, Sisira

AU - Rodrigues, George

AU - Rogan, Peter K.

AU - Hoch, Jeffrey S

AU - Zaric, Gregory S.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose The purpose of this study was to estimate the incidence of occult gastrointestinal (GI) primary tumours in patients with metastatic cancer of uncertain primary origin and evaluate their influence on treatments and overall survival (OS). Materials and Methods We used population heath data from Manitoba, Canada to identify all patients initially diagnosed with metastatic cancer between 2002 and 2011. We defined patients to have "occult" primary tumour if the primary was found at least 6 months after initial diagnosis. Otherwise, we considered primary tumours as "obvious." We used propensity-score methods to match each patient with occult GI tumour to four patients with obvious GI tumour on all known clinicopathologic features. We compared treatments and 2-year survival data between the two patient groups and assessed treatment effect on OS using Cox regression adjustment. Results Eighty-three patients had occult GI primary tumours, accounting for 17.6% of men and 14% of women with metastatic cancer of uncertain primary. A 1:4 matching created a matched group of 332 patients with obvious GI primary tumour. Occult cases compared to the matched group were less likely to receive surgical interventions and targeted biological therapy, and more likely to receive cytotoxic empiric chemotherapeutic agents. Having an occult GI tumour was associated with reduced OS and appeared to be a nonsignificant independent predictor of OS when adjusting for treatment differences. Conclusion GI tumours are the most common occult primary tumours in men and the second most common in women. Patients with occult GI primary tumours are potentially being undertreated with available GI site-specific and targeted therapies.

AB - Purpose The purpose of this study was to estimate the incidence of occult gastrointestinal (GI) primary tumours in patients with metastatic cancer of uncertain primary origin and evaluate their influence on treatments and overall survival (OS). Materials and Methods We used population heath data from Manitoba, Canada to identify all patients initially diagnosed with metastatic cancer between 2002 and 2011. We defined patients to have "occult" primary tumour if the primary was found at least 6 months after initial diagnosis. Otherwise, we considered primary tumours as "obvious." We used propensity-score methods to match each patient with occult GI tumour to four patients with obvious GI tumour on all known clinicopathologic features. We compared treatments and 2-year survival data between the two patient groups and assessed treatment effect on OS using Cox regression adjustment. Results Eighty-three patients had occult GI primary tumours, accounting for 17.6% of men and 14% of women with metastatic cancer of uncertain primary. A 1:4 matching created a matched group of 332 patients with obvious GI primary tumour. Occult cases compared to the matched group were less likely to receive surgical interventions and targeted biological therapy, and more likely to receive cytotoxic empiric chemotherapeutic agents. Having an occult GI tumour was associated with reduced OS and appeared to be a nonsignificant independent predictor of OS when adjusting for treatment differences. Conclusion GI tumours are the most common occult primary tumours in men and the second most common in women. Patients with occult GI primary tumours are potentially being undertreated with available GI site-specific and targeted therapies.

KW - Cohort studies

KW - Gastrointestinal neoplasms

KW - Information storage and retrieval

KW - Neoplasm metastasis

KW - Propensity score

KW - Research design

KW - Unknown primary neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85040453944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040453944&partnerID=8YFLogxK

U2 - 10.4143/crt.2016.532

DO - 10.4143/crt.2016.532

M3 - Article

C2 - 28324922

AN - SCOPUS:85040453944

VL - 50

SP - 183

EP - 194

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 1

ER -